Press release
Diabetes and obesity therapeutics market will more than double to $163.2 billion by 2022
The global market for diabetes mellitus and obesity is set to rise from $70.8 billion in 2015 to $163.2 billion by 2022, at a strong compound annual growth rate of 12.7%.
Callum Dew, Associate Analyst for GBI Research, explains: “Recent approvals and pipeline products that are expected to be key players during the forecast period include Tresiba (insulin degludec), Invokana (canagliflozin) and NN-9535 (semaglutide). The disease cluster is dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and T2DM, and the majority of the pipeline, in terms of both quantity and quality of products, is attributable to these indications.
“While products indicated for obesity do not currently have a large market presence, there are a large number of these products in the pipeline, with the majority in early stages of development. Of course, the growth of the disease cluster is driven not only by the rising global incidence of obesity, but also the subsequent effect that this has on T2DM incidence, given the intrinsic link between the two diseases.”
Invokana, which is marketed by Johnson & Johnson, is one of the key players in the disease cluster. It is expected to reach a huge $3.23 billion by 2022, and is set to be approved across T1DM, T2DM and obesity. Although current top-selling drugs such as Januvia, Novolog and Invokana are expected to remain dominant within the disease cluster, four of the anticipated top 10 best-selling drugs of 2022 will be new to market.
Dew concludes: “These products, which include dapagliflozin propanediol plus saxagliptin, NN-9535 and LixiLan, are expected to reach blockbuster status and become key players themselves, indicating the strength and diversity of both the market and the pipeline for diabetes.”
To request free report preview e-mail to - gdreports@globaldata.com?subject=Sample%20Pages%20for%20GBIHC413MR-%20Global%20Diabetes%20and%20Obesity%20Drugs%20Market%20to%202022%20(
GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.
John Carpenter House, John Carpenter Street, London EC4Y 0AN, UK.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Diabetes and obesity therapeutics market will more than double to $163.2 billion by 2022 here
News-ID: 479989 • Views: …
More Releases from GBI Research
Glioblastoma market set for strong innovation, with 120 first-in-class programs
Glioblastoma, a particularly aggressive form of brain tumor, has a promising treatment pipeline, with 120 first-in-class programs acting on 86 first-in-class molecular targets. Adam Bradbury, MSc, Associate Analyst for GBI Research, explains: “Pipeline innovation has far-reaching strategic implications for all market participants as, despite the high attrition rate in glioblastoma, it is highly likely that many of the numerous first-in-class products, a number of which are supported by promising preclinical…
Global drug delivery technologies market will reach $26 billion by 2020
The global market for drug delivery technologies will rise from $20 billion in 2015 to around $26 billion by 2020. Deekshita Allavarapu, Analyst for GBI Research, states: “The size of the US market was estimated to be $6.2 billion in 2015 and is projected to grow at a compound annual growth rate (CAGR) of 4.3% from 2010 to reach $7.7 billion in 2020.
“The US drug delivery technologies market will continue…
Increased diagnoses of hemophilia A and B will drive Asia-Pacific market growth …
The hemophilia A and B markets in the Asia-Pacific (APAC) region are forecast to expand from $444.9 million and $76.3 million in 2015 to $699.1 million and $112.9 million by 2022, representing compound annual growth rates of 6.7% and 5.8%, respectively.
Gayathri Kanika, Analyst for GBI Research, notes: “One of the most pressing unmet needs in the hemophilia space is for a treatment to address inhibitor development, particularly in those…
Cardiovascular disease market set to grow very slowly to $146.4 billion by 2022
The cardiovascular disease market, which includes hypertension, dyslipidemia, and thrombotic events, is set to grow from $129.2 billion in 2015 to $146.4 billion by 2022, at a very modest compound annual growth rate of 1.8%.
Thomas Jarratt, Associate Analyst for GBI Research, explains: “Unlike AstraZeneca, some key players will experience revenue growth resulting from the introduction of new products to market. In particular, Sanofi’s Praluent (alirocumab) is expected to help mitigate…
More Releases for Diabetes
Reverse Diabetes with Dr. Merritt’s Diabetes Reversal Recipe
[November 26, 2020] – People suffering from diabetes always search for ways to lower blood sugar levels in their bodies. Diabetes treatment available costs you hundreds of dollars yearly and also restricts you to a diabetic diet. That hampers your mental health and well-being. Apart from this, eye problems, kidney failure, amputations are some of the physical problems diabetic patients face.
Dr. Marlene Merritt (from the Merritt Wellness Center in…
Emerging trends for Diabetes Care Devices Market 2020 astonishing growth by Worl …
The global diabetes care devices market is expected to reach US$ 39,382.3 Mn in 2027 from US$ 23,354.3 Mn in 2018. The market is estimated to grow with a CAGR of 6.1% from 2020-2027.
Premium market insights recently published a report titled "Diabetes Care Devices Market Size and Forecast to 2026". The report includes an authentic and accurate research study into the global Diabetes Care Devices market based on a qualitative…
Diabetes Treatment
Diabetes Treatment is a important way to help manage the healthy ,easy to use and improve the way of the treatment of blood glucose monitoring system.
As living standards improve, an increasing obesity, the Diabetes Treatment has improved peoples living habits, disease control effect, is becoming more and more important.
The global Diabetes Treatment market is valued at 43700 million US$ in 2018 and will reach 58000 million US$ by the end…
Self-Monitoring Blood Glucose Devices Market Study by Advance Application [Type …
The global self-monitoring blood glucose devices market was valued at $7,768 million in 2017 and is projected to reach $10,828 million by 2025 at a CAGR of 4.2% from 2018 to 2025. Monitoring of blood glucose is an essential step in diabetes management. Blood glucose monitoring devices are predominantly used to monitor a patient’s blood glucose level. Self-monitoring blood glucose (SMBG) devices are easy-to-use and enable people to monitor their…
Global Diabetes Industry
Global Diabetes Industry
Market Insight
Global diabetes market is expected to grow at a CAGR of 7.9% percent for the forecasted period of 2016-2021. The market is segmented on the basis of type of diabetes, drugs class and diabetic devices. Diabetic drugs have the highest market share amongst drugs and devices and are also expected to have the highest growth rate with a CAGR of 9%. Some of the top selling…
Diabetes Drugs Market: Increasing Prevalence of Diabetes to Stoke Market Growth
According to the TMR report, the global diabetes drugs market stood at a valuation of US$43.1 bn in 2016 and is likely to be valued at US$58.4 bn by the end of 2025 expanding at a CAGR of 3.6% between 2017 and 2025.
Research and Development Pursuits to Introduce Novel Products Stokes Growth
The rising per capita income in several parts of world leading to changing lifestyles and adoption of unhealthy food…
